| Heart disease and stroke statistics—2014 update: a report from the American Heart Association AS Go, D Mozaffarian, VL Roger, EJ Benjamin, JD Berry, MJ Blaha, S Dai, ... circulation 129 (3), e28-e292, 2014 | 74969* | 2014 |
| Dapagliflozin and cardiovascular outcomes in type 2 diabetes SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ... New England Journal of Medicine 380 (4), 347-357, 2019 | 6357 | 2019 |
| Semaglutide and cardiovascular outcomes in patients with type 2 diabetes SP Marso, SC Bain, A Consoli, FG Eliaschewitz, E Jódar, LA Leiter, ... New England Journal of Medicine 375 (19), 1834-1844, 2016 | 5779 | 2016 |
| Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus BM Scirica, DL Bhatt, E Braunwald, PG Steg, J Davidson, B Hirshberg, ... New England Journal of Medicine 369 (14), 1317-1326, 2013 | 4312 | 2013 |
| Effects of combination lipid therapy in type 2 diabetes mellitus ACCORD Study Group New England Journal of Medicine 362 (17), 1563-1574, 2010 | 3532 | 2010 |
| SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome … TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich, MP Bonaca, ... The Lancet 393 (10166), 31-39, 2019 | 2798 | 2019 |
| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2557 | 2019 |
| Effects of dalcetrapib in patients with a recent acute coronary syndrome GG Schwartz, AG Olsson, M Abt, CM Ballantyne, PJ Barter, J Brumm, ... New England Journal of Medicine 367 (22), 2089-2099, 2012 | 2327 | 2012 |
| Cardiorenal end points in a trial of aliskiren for type 2 diabetes HH Parving, BM Brenner, JJV McMurray, D De Zeeuw, SM Haffner, ... New England Journal of Medicine 367 (23), 2204-2213, 2012 | 1680 | 2012 |
| Sotagliflozin in patients with diabetes and recent worsening heart failure DL Bhatt, M Szarek, PG Steg, CP Cannon, LA Leiter, DK McGuire, ... New England journal of medicine 384 (2), 117-128, 2021 | 1646 | 2021 |
| Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society consensus panel statement on assessment, aetiology and management ES Stroes, PD Thompson, A Corsini, GD Vladutiu, FJ Raal, KK Ray, ... European heart journal 36 (17), 1012-1022, 2015 | 1597 | 2015 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ... The Lancet 392 (10157), 1519-1529, 2018 | 1484 | 2018 |
| Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol KK Ray, RS Wright, D Kallend, W Koenig, LA Leiter, FJ Raal, JA Bisch, ... New England journal of medicine 382 (16), 1507-1519, 2020 | 1206 | 2020 |
| 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult TJ Anderson, J Grégoire, RA Hegele, P Couture, GBJ Mancini, ... Canadian Journal of Cardiology 29 (2), 151-167, 2013 | 1122 | 2013 |
| 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult TJ Anderson, J Grégoire, GJ Pearson, AR Barry, P Couture, M Dawes, ... Canadian Journal of Cardiology 32 (11), 1263-1282, 2016 | 1082 | 2016 |
| 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult–2009 recommendations J Genest, R McPherson, J Frohlich, T Anderson, N Campbell, ... Canadian Journal of Cardiology 25 (10), 567-579, 2009 | 1066 | 2009 |
| Cholesterol lowering in intermediate-risk persons without cardiovascular disease S Yusuf, J Bosch, G Dagenais, J Zhu, D Xavier, L Liu, P Pais, ... New England Journal of Medicine 374 (21), 2021-2031, 2016 | 1047 | 2016 |
| Sotagliflozin in patients with diabetes and chronic kidney disease DL Bhatt, M Szarek, B Pitt, CP Cannon, LA Leiter, DK McGuire, JB Lewis, ... New England Journal of Medicine 384 (2), 129-139, 2021 | 1010 | 2021 |
| Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol KK Ray, U Landmesser, LA Leiter, D Kallend, R Dufour, M Karakas, T Hall, ... New England Journal of Medicine 376 (15), 1430-1440, 2017 | 998 | 2017 |
| Effect of valsartan on the incidence of diabetes and cardiovascular events NAVIGATOR Study Group New England Journal of Medicine 362 (16), 1477-1490, 2010 | 951 | 2010 |
